Department of Radiation Oncology, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
BJU Int. 2018 Apr;121(4):540-548. doi: 10.1111/bju.14021. Epub 2017 Oct 17.
To provide comparative data on quality of life (QoL) after prostate cancer treatment to help patients make an informed decision regarding their choice of treatment.
Patients with pathologically proven, non-metastatic, T1-T3bN0 prostate cancer were included in this prospective non-randomized study if they were to receive treatment with curative intent. Sample size was at least 181 patients per cohort/treatment type. QoL was recorded at baseline and at each follow-up using the Expanded Prostate Cancer Index Composite (EPIC) instrument. The minimal clinically important difference was defined as half of the standard deviation of the baseline score for each domain. A mixed effects model was used to compare the different treatments. Data are presented on the brachytherapy and the bilateral nerve-sparing robot-assisted radical prostatectomy (RARP) cohorts. Hormonotherapy was not allowed.
Between November 2007 and January 2013, 181 patients who received brachytherapy and 210 patients who underwent RARP were included. Of the patients who underwent RARP, 178 had bilateral nerve-sparing and were included in the present analysis. Response rate to EPIC questionnaires were higher in the brachytherapy than in the RARP arm: 82% vs 57% at 2 years after treatment and 55% vs 45% at 4 years after treatment. In the mixed effects model, patients in the RARP arm had better QoL with regard to urinary irritation/obstruction or bother and bowel function, and lower QoL regarding sexual function and urinary incontinence. Results were confirmed in a propensity score-matched model. Patient satisfaction was significantly higher in the brachytherapy group at 1, 2 and 3 years after treatment.
This prospective non-randomized study shows long-term differences in QoL domains after bilateral nerve-sparing RARP and brachytherapy. Differences in patient satisfaction should be further explored. These results could be used to counsel patients in the decision-making process.
提供前列腺癌治疗后生活质量(QoL)的对比数据,帮助患者做出有关治疗选择的知情决策。
本前瞻性非随机研究纳入了接受根治性治疗的病理证实、无转移、T1-T3bN0 前列腺癌患者。每队列/治疗类型的样本量至少为 181 例患者。使用扩展前列腺癌指数综合量表(EPIC)在基线和每次随访时记录 QoL。最小临床重要差异定义为每个域基线评分标准差的一半。使用混合效应模型比较不同的治疗方法。报告了近距离放射治疗和双侧神经保留机器人辅助根治性前列腺切除术(RARP)队列的数据。不允许使用激素治疗。
2007 年 11 月至 2013 年 1 月,共纳入 181 例接受近距离放射治疗和 210 例接受 RARP 的患者。在接受 RARP 的患者中,178 例接受了双侧神经保留,并纳入本分析。EPIC 问卷的应答率在近距离放射治疗组高于 RARP 组:治疗后 2 年分别为 82%和 57%,治疗后 4 年分别为 55%和 45%。在混合效应模型中,RARP 组患者在尿刺激/梗阻或困扰和肠道功能方面的 QoL 更好,在性功能和尿失禁方面的 QoL 更差。在倾向评分匹配模型中得到了证实。治疗后 1、2 和 3 年,近距离放射治疗组患者的满意度显著更高。
本前瞻性非随机研究显示双侧神经保留 RARP 和近距离放射治疗后 QoL 领域的长期差异。患者满意度的差异应进一步探讨。这些结果可用于在决策过程中为患者提供咨询。